A phase IIb open label, randomized clinical trial evaluating efficacy and safety of Myrcludex B in combination with tenofovir in patients with chronic hepatitis B and D co-infections

Trial Profile

A phase IIb open label, randomized clinical trial evaluating efficacy and safety of Myrcludex B in combination with tenofovir in patients with chronic hepatitis B and D co-infections

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Myrcludex-B (Primary) ; Tenofovir
  • Indications Hepatitis B; Hepatitis D
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2017 Interim results presented in a Maxwell Biotech media release.
    • 28 Nov 2017 Primary endpoint (Hepatitis D virus RNA negativation or decrease by 2log10) has been met, according to a Maxwell Biotech media release.
    • 24 Oct 2017 Interim results assessing safety and efficacy presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top